Lipoprotein Particles As Shuttles for Hydrophilic Cargo

Overview

Journal Membranes (Basel)

Date 2023 May 26

PMID 37233532

Authors

Florian Weber

Markus Axmann

Andreas Horner

Bettina Schwarzinger

Julian Weghuber

Birgit Plochberger

Affiliations

Soon will be listed here.

Abstract

Lipoprotein particles (LPs) are excellent transporters and have been intensively studied in cardiovascular diseases, especially regarding parameters such as their class distribution and accumulation, site-specific delivery, cellular internalization, and escape from endo/lysosomal compartments. The aim of the present work is the hydrophilic cargo loading of LPs. As an exemplary proof-of-principle showcase, the glucose metabolism-regulating hormone, insulin, was successfully incorporated into high-density lipoprotein (HDL) particles. The incorporation was studied and verified to be successful using Atomic Force Microscopy (AFM) and Fluorescence Microscopy (FM). Single-molecule-sensitive FM together with confocal imaging visualized the membrane interaction of single, insulin-loaded HDL particles and the subsequent cellular translocation of glucose transporter type 4 (Glut4).

References

Brown M, Goldstein J . Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc Natl Acad Sci U S A. 1979; 76(7):3330-7. PMC: 383819. DOI: 10.1073/pnas.76.7.3330. View

Sakurai T, Takeda S, Takahashi J, Takahashi Y, Wada N, Trirongjitmoah S . Measurement of single low-density lipoprotein particles by atomic force microscopy. Ann Clin Biochem. 2013; 50(Pt 6):564-70. DOI: 10.1177/0004563213481586. View

Chuang S, Cruz S, Narayanaswami V . Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents. Nanomaterials (Basel). 2020; 10(5). PMC: 7279153. DOI: 10.3390/nano10050906. View

Kraft J, Freeling J, Wang Z, Ho R . Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci. 2013; 103(1):29-52. PMC: 4074410. DOI: 10.1002/jps.23773. View

Huang H, Cruz W, Chen J, Zheng G . Learning from biology: synthetic lipoproteins for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014; 7(3):298-314. PMC: 4397116. DOI: 10.1002/wnan.1308. View

Mooberry L, Sabnis N, Panchoo M, Nagarajan B, Lacko A . Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging. Front Pharmacol. 2016; 7:466. PMC: 5156841. DOI: 10.3389/fphar.2016.00466. View

Shen W, Azhar S, Kraemer F . SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. Annu Rev Physiol. 2017; 80:95-116. PMC: 6376870. DOI: 10.1146/annurev-physiol-021317-121550. View

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

Kastelein J, van der Steeg W, Holme I, Gaffney M, Cater N, Barter P . Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008; 117(23):3002-9. DOI: 10.1161/CIRCULATIONAHA.107.713438. View

10.

Pownall H, Rosales C, Gillard B, Ferrari M . Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism. Methodist Debakey Cardiovasc J. 2016; 12(3):146-150. PMC: 5098571. DOI: 10.14797/mdcj-12-3-146. View

11.

Tokunaga M, Imamoto N, Sakata-Sogawa K . Highly inclined thin illumination enables clear single-molecule imaging in cells. Nat Methods. 2008; 5(2):159-61. DOI: 10.1038/nmeth1171. View

12.

Wang K, Li Y, Luo C, Chen Y . Dynamic AFM detection of the oxidation-induced changes in size, stiffness, and stickiness of low-density lipoprotein. J Nanobiotechnology. 2020; 18(1):167. PMC: 7664080. DOI: 10.1186/s12951-020-00727-x. View

13.

Yvan-Charvet L, Wang N, Tall A . Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2009; 30(2):139-43. PMC: 2812788. DOI: 10.1161/ATVBAHA.108.179283. View

14.

Blanchette C, Cappuccio J, Kuhn E, Segelke B, Benner W, Chromy B . Atomic force microscopy differentiates discrete size distributions between membrane protein containing and empty nanolipoprotein particles. Biochim Biophys Acta. 2008; 1788(3):724-31. DOI: 10.1016/j.bbamem.2008.11.019. View

15.

Plochberger B, Axmann M, Rohrl C, Weghuber J, Brameshuber M, Rossboth B . Direct observation of cargo transfer from HDL particles to the plasma membrane. Atherosclerosis. 2018; 277:53-59. DOI: 10.1016/j.atherosclerosis.2018.08.032. View

16.

Goldstein J, Brown M . The LDL receptor. Arterioscler Thromb Vasc Biol. 2009; 29(4):431-8. PMC: 2740366. DOI: 10.1161/ATVBAHA.108.179564. View

17.

Axmann M, Strobl W, Plochberger B, Stangl H . Cholesterol transfer at the plasma membrane. Atherosclerosis. 2019; 290:111-117. DOI: 10.1016/j.atherosclerosis.2019.09.022. View

18.

Lund-Katz S, Phillips M . High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem. 2010; 51:183-227. PMC: 3215094. DOI: 10.1007/978-90-481-8622-8_7. View

19.

Pardridge W . Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012; 32(11):1959-72. PMC: 3494002. DOI: 10.1038/jcbfm.2012.126. View

20.

Boullier A, Witztum J, Steinberg D, Quehenberger O . Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res. 2001; 42(9):1474-82. View